Baylor College of Medicine, Houston, TX
Samer Al Hadidi , Deepa Dongarwar , Hamisu Salihu , Rammurti T. Kamble , Premal D. Lulla , LaQuisa Hill , George Carrum , Carlos Almeida Ramos , Helen E. Heslop , Saad Zafar Usmani
Background: Multiple Myeloma (MM) is the most common hematologic malignancy in Black Americans. Incidence and death rates for MM in Black Americans are more than double those in Whites. Our study aimed to evaluate trends of all cause in-hospital mortality among Black Americans with MM and to investigate characteristics of MM-related hospitalizations. Methods: We conducted a retrospective cross-sectional study of hospitalizations in adult patients with MM during 2008-2017 using the National Inpatient Sample (NIS), the largest all-payer inpatient care database in the US. We used joinpoint regression to assess temporal trends in the national incidence of in-hospital death. We conducted adjusted survey logistic regression to generate adjusted odds ratios to measure the likelihood of in-hospital death among MM related hospitalizations. Results: Admissions related to MM constituted 0.32% of all hospitalizations in the study period (913,967 out of 285,876,821). The prevalence of MM related hospitalizations was higher in Black Americans when compared with Whites (476.0 vs 305.6 per 100,000 hospitalizations, p <0.01). In-hospital mortality with MM was higher in older patients, males, those belonging to lowest zip code quartile, and who self-paid for their treatment. Average Annual Percent Change (AAPC) showed a statistically significant decline of in-hospital mortality among all MM patients except Black Americans who had the highest inpatient mortality in 2016 and 2017. Black Americans received less autologous stem cell transplantation (ASCT) (2.8% vs. 3.8%, p <0.01), more blood product transfusions (23.0% vs. 21.1%, p <0.01), less palliative care consultation (4.0% vs. 4.6%, p <0.01), less chemotherapy (10.8% vs. 11.2%, p <0.01), and more intensive care utilization (5.3% vs. 4.3%, p <0.01), when compared with Whites. Adjusted association between race/ethnicity and various outcomes confirmed observed differences [Table]. Conclusions: Black Americans with MM had the slowest improvement and highest inpatient mortality in recent years. Data suggests higher disease burden, more frequent hospitalizations, delay in accessing care and lower utilization of supportive care measures compared with White MM patients. Data highlight disparities in MM care for Black Americans necessitating a clarion call for urgent changes in health care systems.
OR (95% CI) | P-value | |
---|---|---|
In-hospital death White Black Hispanic | Ref 1.02 (0.96-1.08) 0.99 (0.9-1.08) | 0.5 0.74 |
ASCT White Black Hispanic | Ref 0.68 (0.58-0.79) 0.91 (0.74-1.12) | < 0.01 0.38 |
Blood product transfusion White Black Hispanic | Ref 1.12 (1.06-1.18) 1.01 (0.92-1.1) | < 0.01 0.9 |
Chemotherapy use White Black Hispanic | Ref 0.91 (0.84-0.98) 1.04 (0.92-1.18) | 0.02 0.52 |
Palliative care consultation White Black Hispanic | Ref 0.91 (0.85-0.97) 0.83 (0.75-0.93) | 0.01 < 0.01 |
ICU utilization White Black Hispanic | Ref 1.24 (1.17-1.32) 1.00 (0.91-1.11) | < 0.01 0.95 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Zunairah Shah
2023 ASCO Annual Meeting
First Author: Kavya Bharathidasan
2024 ASCO Annual Meeting
First Author: Arun Kumar
2023 ASCO Annual Meeting
First Author: Ayobami Gbenga Olafimihan